Amyloid Beta A4 Protein, commonly referred to as Amyloid-beta (Aβ), is a peptide that is crucially involved in the pathogenesis of Alzheimer’s disease. The mouse anti-human Amyloid Beta A4 Protein antibody is a monoclonal antibody used extensively in research to study the properties and effects of Amyloid-beta in human samples.
Amyloid-beta is derived from the Amyloid Precursor Protein (APP), a transmembrane protein that is expressed in many tissues, including the brain. APP can be processed through two main pathways: the non-amyloidogenic pathway and the amyloidogenic pathway. The latter involves the sequential cleavage of APP by β-secretase and γ-secretase, resulting in the production of Amyloid-beta peptides of varying lengths, predominantly Aβ40 and Aβ42 .
Amyloid-beta peptides are known to aggregate and form insoluble fibrils that deposit as amyloid plaques in the brains of Alzheimer’s disease patients. These plaques are one of the hallmark pathological features of the disease. The accumulation of Amyloid-beta is believed to disrupt cell-to-cell communication and activate immune responses that lead to inflammation and neuronal cell death .
The mouse anti-human Amyloid Beta A4 Protein antibody is a monoclonal antibody that specifically binds to epitopes within the Amyloid-beta peptide. This antibody is used in various applications, including immunoprecipitation (IP), Western blotting (WB), immunohistochemistry on paraffin-embedded sections (IHC-P), immunocytochemistry/immunofluorescence (ICC/IF), and immunohistochemistry on frozen sections (IHC-Fr) .